Back toUpdated on October 25, 2024
In previous decades, donated blood was not screened for hepatitis C, and this could have negatively impacted transfusions for sickle cell anemia.
Transcript
Hey, Dr. McCutchen. How important is diversity when it comes to clinical trials for hepatitis C medication? [MUSIC PLAYING]
The US Department of Health and Human Services Office of Minority Health found that in 2018, African-Americans were nearly twice as likely to die from
hepatitis C compared to white people. In a 2020 study found that Black Americans accounted for up to 23% of diagnosed hepatitis C
in the United States. Why? It may have something to do with blood transfusions and the treatment of sickle cell disease.
Black Americans are more likely to have sickle cell disease, an inherited blood disorder that can be treated in part
with blood transfusions. You see, if you donate blood today, there is a required screening to check for diseases prior
to a transfusion. However, just 30 years ago, screenings for donating blood were non-existent.
Hepatitis C is spread through the blood, such as through blood transfusions, sharing of needles, and getting a tattoo or body piercing
with an infected needle. But symptoms don't develop immediately. So not long ago, someone could have had a hepatitis C
infection, not know it, and donate blood and pass the virus on to someone seeking a blood transfusion for sickle cell.
Thankfully, since 1992, diseases are rarely transmitted through blood transfusions due to mandatory screenings.
However, the impact of the sickle cell blood transfusions before 1992 are still affecting Black Americans today
at a disproportionate rate. You see, if a mother has hepatitis C virus, she can pass it on to her unborn child.
This leads to an unfortunate cycle of transmitting the virus through generations. The Black population in America is
less likely to have a sustained viral response to treatment. In addition, they are more likely to be deemed
ineligible to receive treatment for their hepatitis C infections as opposed to their racial counterparts.
Although the clinical evidence is not clear as to why this population is more often deemed ineligible for treatment of hepatitis C,
though it could be due to a variety of factors, including limited representation in clinical trials.
Hepatitis C can be life threatening, and if you haven't already, it is recommended you get screened for it.
If you're over 18 the CDC recommends a screening, at least once in your life for all adults up to age 79.
Talk to your health care provider to learn more. [MUSIC PLAYING]
